Synapse - MSK Grad Students

Results (2841)

First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL

Meeting Abstract

Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)

Meeting Abstract

Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
Blood (2021)

Fulltext@MSK | Save

Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease

Meeting Abstract

Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
Blood (2021)

Fulltext@MSK | Save

Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy

Meeting Abstract

Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

A phase II study of ruxolitinib pre-, during- and post-hematopoietic celltransplantation for patients with primary or secondary myelofibrosis

Meeting Abstract

Hobbs, G.; Kim, H. T.; Bottoms, A. J. S.; Byrne, M. T.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; Defilipp, Z.; El-Jawahri, A.; McAfee, S.; more...
Blood (2021)

Fulltext@MSK | Save

Racial disparities in access to alternative donor allografts persist in the era of "Donors for all"

Meeting Abstract

Fingrut, W.; Politikos, I.; Davis, E.; Chinapen, S.; Naputo, K.; Cho, C.; Giralt, S. A.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; more...
Blood (2021)

Fulltext@MSK | Save

TP53 mutations and RNA binding protein MUSASHI 2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

Meeting Abstract

Erazo, I. T.; Evans, C. M.; Zakheim, D.; Chu, K. L.; Barbash, O.; Refermat, A. Y.; Batlevi, C. L.; Younes, A.; Kharas, M. G.
Blood (2021)

Fulltext@MSK | Save

Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience

Meeting Abstract

Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood (2021)

Fulltext@MSK | Save

Nutrition as a predictor of microbiome injury in allo-HCT

Meeting Abstract

Dai, A.; Adintori, P. A.; Docampo, M. D.; Brambilla, C. Z.; Buchan, M. L.; Gomes, A. L.; Burgos da Silva, M. D.; Markey, K. A.; Devlin, S. M.; Clurman, A.; more...
Blood (2021)

Fulltext@MSK | Save

Non-relapse mortality in TP53-mutated MDS/AML - A multi-center collaborative study

Meeting Abstract

Byrne, M. T.; Kurian, T. J.; Patel, D. A.; Tamari, R.; Hong, S.; Abdelhakim, H.; Klein, V.; Rojas, P.; Madhavan, R.; Kent, A.; more...
Blood (2021)

Fulltext@MSK | Save